Cargando…

High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B

INTRODUCTION: There is no data on the relationship between hepatitis B surface antigen (HBsAg) levels and liver fibrosis in hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B (CHB). METHODS: Serum HBsAg and HBV DNA levels in HBeAg-positive CHB patients with liver biopsies were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seto, Wai-Kay, Wong, Danny Ka-Ho, Fung, James, Ip, Philip P. C., Yuen, John Chi-Hang, Hung, Ivan Fan-Ngai, Lai, Ching-Lung, Yuen, Man-Fung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423440/ https://www.ncbi.nlm.nih.gov/pubmed/22916211 http://dx.doi.org/10.1371/journal.pone.0043087

Ejemplares similares

Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Mak, Lung-Yi, et al.
Publicado: (2020)

Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance
por: Zheng, Ming-Hua, et al.
Publicado: (2014)

Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
por: Hui, Ka-Yin, et al.
Publicado: (2023)

A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2023)

The use of transient elastography in the management of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2011)

New Biomarkers of Chronic Hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2019)

Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection
por: Huang, Fung-Yu, et al.
Publicado: (2014)

Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma
por: Zhang, An-Ye, et al.
Publicado: (2015)

A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2011)

Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B
por: Fung, James, et al.
Publicado: (2010)

Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection
por: Mak, Lung-Yi, et al.
Publicado: (2018)

Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011)

Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed
por: Lai, Ching-Lung, et al.
Publicado: (2020)

Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
por: Lam, Lok-Ka, et al.
Publicado: (2023)

The role of different viral biomarkers on the management of chronic hepatitis B
por: Mak, Lung-Yi, et al.
Publicado: (2023)

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma
por: Hung, Ivan Fan-Ngai, et al.
Publicado: (2016)

Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
por: Mak, Lung-Yi, et al.
Publicado: (2019)

Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment
por: Cheung, Ka-Shing, et al.
Publicado: (2017)

Role of HLA-DP Polymorphisms on Chronicity and Disease Activity of Hepatitis B Infection in Southern Chinese
por: Wong, Danny Ka-Ho, et al.
Publicado: (2013)

RNA interference as a novel treatment strategy for chronic hepatitis B infection
por: Hui, Rex Wan-Hin, et al.
Publicado: (2022)

Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
por: Cheung, Ka Shing, et al.
Publicado: (2020)

Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma
por: Huang, Fung-Yu, et al.
Publicado: (2021)

Serum hepatitis B surface antigen titer and transient elastography in screening for insignificant fibrosis in HBeAg-positive chronic hepatitis B patients
por: Liang, Ling-Bo, et al.
Publicado: (2015)

Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study
por: Kan, Karin, et al.
Publicado: (2023)

Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection
por: Hsu, Axel, et al.
Publicado: (2011)

The Role of Steatosis in HBsAg Seroclearance for Patients with Chronic Hepatitis B Infection: Fact or Fiction?
por: Fung, James, et al.
Publicado: (2012)

Serum hepatitis B surface antigen levels predict insignificant fibrosis and non-cirrhosis in hepatitis B e antigen positive patients with normal or mildly elevated alanine transaminase levels
por: Li, Qiang, et al.
Publicado: (2017)

RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
por: Yuen, Man‐Fung, et al.
Publicado: (2020)

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
por: Cheung, Ka Shing, et al.
Publicado: (2022)

Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials
por: Tran, Tram T., et al.
Publicado: (2015)

Correlation Between Quantitative Hepatitis B Surface Antigen and Hepatitis B Virus Deoxyribonucleic Acid Levels in Hepatitis B e Antigen-Positive and Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
por: Nirmala, Viva Finhar Insani, et al.
Publicado: (2023)

Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction
por: Zhang, Saisai, et al.
Publicado: (2022)

Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients
por: Cheung, Ka Shing, et al.
Publicado: (2023)

On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B
por: Chang, Xiu-Juan, et al.
Publicado: (2019)

Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B
por: Li, Ming-Hui, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_721ju82m1q1hcu2cecq62pch9o